Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 20;5(4):103329.
doi: 10.1016/j.xpro.2024.103329. Epub 2024 Sep 28.

Protocol to generate, purify, and analyze antibody-oligonucleotide conjugates from off-the-shelf antibodies

Tony Rady  1 , Victor Lehot  2 , Julien Most  2 , Stephane Erb  3 , Sarah Cianferani  3 , Guilhem Chaubet  2 , Nicolas Basse  4 , Alain Wagner  2
Affiliations

Protocol to generate, purify, and analyze antibody-oligonucleotide conjugates from off-the-shelf antibodies

Tony Rady et al. STAR Protoc. .

Abstract

Antibody-oligonucleotide conjugates (AOCs) are a fast-expanding modality for targeted delivery of therapeutic oligonucleotides to tissues. Here, we present a protocol to generate, purify, and analyze AOCs from off-the-shelf antibodies. We describe steps to conjugate single/double-stranded oligonucleotides bearing amine handles to linkers and, then, to antibodies using well-established chemistry. In addition, we provide details regarding the purification techniques and analytical methods suitable for AOC. This protocol can be applied for several purposes where AOC is a modality of interest. For complete details on the use and execution of this protocol, please refer to Rady et al.1.

Keywords: Antibody; Chemistry; Molecular/Chemical Probes.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

None
Graphical abstract
Figure 1
Figure 1
Conjugation of amine-modified oligonucleotide using BCN-PEG6-PFP linker and hybridization with complementary sequence
Figure 2
Figure 2
Mechanism of pH-mediated cleavage of RNA molecules
Figure 3
Figure 3
Lysine conjugation of antibody using ABF
Figure 4
Figure 4
Conjugation of BCN-siRNA to antibody-azide to generate antibody-siRNA conjugates
Figure 5
Figure 5
Representative purification SEC profile obtained after conjugation of siRNA to antibody
Figure 6
Figure 6
Comparison of SEC-MS profile obtained when hybridization is performed before or after antibody conjugation (A) Representative mass spectrum of antibody-siRNA conjugates. (B) Representative mass spectrum of antibody-siRNA conjugates if the hybridization step is performed after the conjugation to the antibody.
See this image and copyright information in PMC

References

    1. Rady T., Erb S., Deddouche-Grass S., Morales R., Chaubet G., Cianférani S., Basse N., Wagner A. Targeted delivery of immune-stimulating bispecific RNA, inducing apoptosis and anti-tumor immunity in cancer cells. iScience. 2024;27 doi: 10.1016/j.isci.2024.109068. - DOI - PMC - PubMed
    1. Thakur S., Sinhari A., Jain P., Jadhav H.R. A perspective on oligonucleotide therapy: Approaches to patient customization. Front. Pharmacol. 2022;13 doi: 10.3389/fphar.2022.1006304. - DOI - PMC - PubMed
    1. Kulkarni J.A., Witzigmann D., Thomson S.B., Chen S., Leavitt B.R., Cullis P.R., van der Meel R. The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 2021;16:630–643. doi: 10.1038/s41565-021-00898-0. - DOI - PubMed
    1. Alshaer W., Zureigat H., Al Karaki A., Al-Kadash A., Gharaibeh L., Hatmal M.M., Aljabali A.A.A., Awidi A. siRNA: Mechanism of action, challenges, and therapeutic approaches. Eur. J. Pharmacol. 2021;905 doi: 10.1016/j.ejphar.2021.174178. - DOI - PubMed
    1. Hu B., Zhong L., Weng Y., Peng L., Huang Y., Zhao Y., Liang X.-J. Therapeutic siRNA: state of the art. Signal Transduct. Target. Ther. 2020;5:101–125. doi: 10.1038/s41392-020-0207-x. - DOI - PMC - PubMed

Publication types